 Shares of Voyager Therapeutics Inc. VYGR, 10.65 rallied 35 in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX, 0.06 to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinsons disease. Neurocrine will make a 175 million upfront payment, including a 39 million equity investment, with up to 1.5 billion in potential milestones. 